These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
935 related articles for article (PubMed ID: 33995389)
1. Reactions Related to CAR-T Cell Therapy. Miao L; Zhang Z; Ren Z; Li Y Front Immunol; 2021; 12():663201. PubMed ID: 33995389 [TBL] [Abstract][Full Text] [Related]
2. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy. Hughes AD; Teachey DT; Diorio C Semin Immunopathol; 2024 Jul; 46(3-4):5. PubMed ID: 39012374 [TBL] [Abstract][Full Text] [Related]
3. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies. Siegler EL; Kenderian SS Front Immunol; 2020; 11():1973. PubMed ID: 32983132 [TBL] [Abstract][Full Text] [Related]
4. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment. Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K Front Immunol; 2021; 12():611366. PubMed ID: 33708205 [TBL] [Abstract][Full Text] [Related]
5. Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy. Walton ZE; Frigault MJ; Maus MV Expert Opin Pharmacother; 2024 Feb; 25(3):263-279. PubMed ID: 38588525 [TBL] [Abstract][Full Text] [Related]
6. Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities. Schroeder T; Martens T; Fransecky L; Valerius T; Schub N; Pott C; Baldus C; Stölzel F Intensive Care Med; 2024 Sep; 50(9):1459-1469. PubMed ID: 39172238 [TBL] [Abstract][Full Text] [Related]
7. Need for standardization of cytokine profiling in CAR T cell therapy. Biery DN; Turicek DP; Diorio C; Schroeder BA; Shah NN Mol Ther; 2024 Sep; 32(9):2979-2983. PubMed ID: 38532629 [TBL] [Abstract][Full Text] [Related]
9. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist. Ong SY; Baird JH J Intensive Care Med; 2024 Oct; 39(10):929-938. PubMed ID: 37899577 [TBL] [Abstract][Full Text] [Related]
11. Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies. Yang C; Nguyen J; Yen Y J Biomed Sci; 2023 Oct; 30(1):89. PubMed ID: 37864230 [TBL] [Abstract][Full Text] [Related]
12. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Hines MR; Knight TE; McNerney KO; Leick MB; Jain T; Ahmed S; Frigault MJ; Hill JA; Jain MD; Johnson WT; Lin Y; Mahadeo KM; Maron GM; Marsh RA; Neelapu SS; Nikiforow S; Ombrello AK; Shah NN; Talleur AC; Turicek D; Vatsayan A; Wong SW; Maus MV; Komanduri KV; Berliner N; Henter JI; Perales MA; Frey NV; Teachey DT; Frank MJ; Shah NN Transplant Cell Ther; 2023 Jul; 29(7):438.e1-438.e16. PubMed ID: 36906275 [TBL] [Abstract][Full Text] [Related]
13. [Research Progress on the Influence of Blood Tumor Microen-vironment on the Efficacy and the Adverse Reactions of CAR-T Cell Immunotherapy--Review]. Liao CF; Lai HR; Li J Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):1290-1294. PubMed ID: 39192433 [TBL] [Abstract][Full Text] [Related]
14. Very unusual extremely high ferritin with cytokine release syndrome in a patient with hematological malignancy after experimental chimeric antigen receptor (CAR)-T-Cell therapy. Hoyt R; Ye Z; Dasgupta A Clin Chim Acta; 2024 Jun; 559():119704. PubMed ID: 38697457 [TBL] [Abstract][Full Text] [Related]
16. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Kotch C; Barrett D; Teachey DT Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357 [No Abstract] [Full Text] [Related]
17. A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy. Zu C; Wu S; Zhang M; Wei G; Xu H; Cui J; Chang AH; Huang H; Hu Y Cytotherapy; 2023 Nov; 25(11):1167-1175. PubMed ID: 37480884 [TBL] [Abstract][Full Text] [Related]
18. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Freyer CW; Porter DL J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558 [TBL] [Abstract][Full Text] [Related]
19. Current understanding and management of CAR T cell-associated toxicities. Brudno JN; Kochenderfer JN Nat Rev Clin Oncol; 2024 Jul; 21(7):501-521. PubMed ID: 38769449 [TBL] [Abstract][Full Text] [Related]
20. The critical role of endothelial cell in the toxicity associated with chimeric antigen receptor T cell therapy and intervention strategies. Zhang Q; Zhu X; Xiao Y Ann Hematol; 2024 Jul; 103(7):2197-2206. PubMed ID: 38329486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]